<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00295555</url>
  </required_header>
  <id_info>
    <org_study_id>7332-2</org_study_id>
    <nct_id>NCT00295555</nct_id>
  </id_info>
  <brief_title>Doxazosin Effects on ABPM in Hypertensive Patients With Diabetic Nephropathy</brief_title>
  <official_title>Effects of Doxazosin on Ambulatory Blood Pressure and Sympathetic Nervous Activity in Hypertensive Patients With Diabetic Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yokohama City University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yokohama City University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Few studies have reported the effect of alpha1-adrenergic antagonists on 24-h blood pressure
      and regulation of sympathetic nervous activity in hypertensive patients with diabetic
      nephropathy. Using ambulatory blood pressure monitoring devices equipped with spectral
      analysis of heart rate variability, we assess the effects of doxazosin on blood pressure in
      diabetic nephropathy patients and compare the results with those in patients with essential
      hypertension, patients with diabetes mellitus and patients with chronic nephropathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is an open-labeled parallel prospective trial comparing the effects of doxazosin
      (2-8 mg/day) on 24-h blood pressure and autonomic nervous activity. Hypertensive patients
      with non-insulin-dependent diabetic nephropathy, patients with essential hypertension,
      patients with diabetes mellitus and patients with chronic nephropathy undergo ambulatory
      blood pressure monitoring before and after treatment with doxazosin. Simultaneously, spectral
      analysis is performed to calculate the high frequency components as a marker of
      parasympathetic nervous activity, and the low frequency components/high frequency components
      ratios as an index of the sympathovagal balance.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Normalization of high blood pressure</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <enrollment type="Actual">98</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Essential Hypertension</condition>
  <condition>Renal Failure</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Effects of doxazosin on morning surge in diabetic patients</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hypertensive patients with diabetes mellitus

          -  Hypertensive patients

          -  Hypertensive patients with renal disease

        Exclusion Criteria:

          -  Cardiac, hematologic or hepatic disease

          -  Renal insufficiency (serum creatinine values&gt; 2 mg/L)

          -  Hormone-induced hypertension

          -  Cerebral infarction or hemorrhage

          -  Other major diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gen Yasuda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yokohama City University Center Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yokohama City University Center Hospital</name>
      <address>
        <city>Yokohama</city>
        <zip>232-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Yasuda G, Hasegawa K, Kuji T, Ogawa N, Shimura G, Umemura S, Tochikubo O. Effects of doxazosin on ambulatory blood pressure and sympathetic nervous activity in hypertensive Type 2 diabetic patients with overt nephropathy. Diabet Med. 2005 Oct;22(10):1394-400.</citation>
    <PMID>16176202</PMID>
  </reference>
  <reference>
    <citation>Yasuda G, Ando D, Hirawa N, Umemura S, Tochikubo O. Effects of losartan and amlodipine on urinary albumin excretion and ambulatory blood pressure in hypertensive type 2 diabetic patients with overt nephropathy. Diabetes Care. 2005 Aug;28(8):1862-8.</citation>
    <PMID>16043724</PMID>
  </reference>
  <reference>
    <citation>Yasuda G, Hasegawa K, Kuji T, Ogawa N, Shimura G, Umemura S, Tochikubo O. Perindopril effects on ambulatory blood pressure: relation to sympathetic nervous activity in subjects with diabetic nephropathy. Am J Hypertens. 2004 Jan;17(1):14-20.</citation>
    <PMID>14700506</PMID>
  </reference>
  <verification_date>April 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2006</study_first_submitted>
  <study_first_submitted_qc>February 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2006</study_first_posted>
  <last_update_submitted>May 8, 2007</last_update_submitted>
  <last_update_submitted_qc>May 8, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2007</last_update_posted>
  <keyword>ambulatory blood pressure monitoring</keyword>
  <keyword>doxazosin</keyword>
  <keyword>alpha1-adrenergic antagonists</keyword>
  <keyword>sympathetic nervous activity</keyword>
  <keyword>diabetic nephropathy</keyword>
  <keyword>essential hypertension</keyword>
  <keyword>power spectral analysis</keyword>
  <keyword>morning surge</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxazosin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

